HackensackUMC Mountainside Cancer Center Leader Honored by Atlantic Hospice

Dr. John A. Conti, medical director of the Cancer Center at HackensackUMC Mountainside, will be honored by the Atlantic Hospice at its annual spring gala on April 8 at the Highlawn Pavilion in West Orange.  

“Dr. Conti is both a skilled oncologist who can offer his patients the most current, effective treatment options and a compassionate practitioner dedicated to providing the finest whole person care,” said John A. Fromhold, FACHE, Chief Executive Officer of HackensackUMC Mountainside.

“Great strides have been made in the treatment of various types of cancer and longevity and survival rates are constantly improving. However, it’s still regrettably among the most common causes of death in our state and nationwide.  Our Cancer Center is fortunate to have a leader who’s capable of handling sensitive end-of-life concerns when necessary,” Fromhold said.  

Along with his role at HackensackUMC Mountainside, Dr. Conti has served as medical director for the Atlantic Hospice for more than a decade. He is a graduate of the Rutgers - New Jersey Medical School (formerly UMDNJ) who completed an oncology fellowship at the Memorial Sloan Kettering Cancer Center in New York City and is board certified in internal medicine, oncology, and hospice and palliative medicine.

Dr. Conti has more than 25 years of professional experience and is a long time member of the Essex Oncology of North Jersey practice with offices in Belleville and at the HackensackUMC Mountainside MultiSpecialty Center on the hospital campus.

“I’m committed to ensuring a multidisciplinary team approach to cancer care, guiding patients through the sometimes complex treatment process and achieving the best outcomes while also alleviating their stress and anxiety,” said Dr. Conti.

“My career as a medical oncologist led me to seek expertise in hospice and palliative medicine so I can bring comfort and dignity to patients in the final phase of life when all anticancer treatment options have been exhausted,” he said.

A Cancer Care Pioneer
Dr. Conti garnered media attention in 2013 by responding to an appeal from a local resident with incurable prostate cancer that had spread to his bones. After securing a New Jersey State Radioactive Materials License for HackensackUMC Mountainside, Dr. Conti administered the state’s first use of Xofigo, a newly approved intravenous drug that had extended life expectancy by as much as 30% in clinical trials.

Produced in Norway, the Xofigo was initially flown to a facility in Colorado where an essential radioactive isotope was added before it was express mailed to Montclair for administration within 48 hours as indicated.  (For more information, visit the Cancer Center web page at mountainsidehosp.com.)

About HackensackUMC Mountainside
HackensackUMC Mountainside has been serving Montclair and its surrounding New Jersey communities since 1891. The hospital, part of the Hackensack University Health Network, provides patients immediate access to innovative and effective treatment alternatives at specialized centers within the hospital that focus on imaging, women’s health, cancer care, surgery, obesity, stroke and chronic kidney disease. HackensackUMC Mountainside is designated as a Primary Stroke Center by the NJ State Department of Health and Senior Services and is one of only a few community hospitals licensed by the State to perform emergency cardiac angioplasty. To learn more about HackensackUMC Mountainside visit www.mountainsidehosp.com



close (X)